Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jon Saxe
AddedMar 31, 2024
UpdatedMay 31, 2026
Jon Saxe

Jon Saxe

Board Member, VistaGen Therapeutics

LinkedIn

Jon Saxe's Career

VistaGen Therapeutics
VistaGen Therapeutics

South San Francisco, CA, US

Board Member· Board
Kyto Technology & Life Science
Kyto Technology & Life Science

Los Altos Hills, CA, US

Board Member· Board
Epalex
Epalex

Palo Alto, CA, US

Board Member· Board
Armetheon
Armetheon

Menlo Park, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jon Saxe's Career

VistaGen Therapeutics
VistaGen Therapeutics
Public332005South San Francisco, CA, US
Board Member· Board

Leadership at VistaGen Therapeutics

Shawn K. SinghShawn K. SinghBoard Member
H. Ralph SnodgrassH. Ralph SnodgrassFounder
Dr Jerry B GinDr Jerry B GinBoard Member

Similar to VistaGen Therapeutics

Psy TherapeuticsPsy TherapeuticsBoston, MA, USDrug Developmentest. 2012Psy TherapeuticsBoston, MA, US · est. 2012

Psy Therapeutics: Innovating novel medicines for CNS disorders like anxiety, depression, and dementia.

Seed · $4M30
Vanda PharmaceuticalsVanda PharmaceuticalsWashington, D.C., DC, USPharmaceuticalsest. 2003Vanda PharmaceuticalsWashington, D.C., DC, US · est. 2003

Vanda Pharmaceuticals, a DC-based biopharmaceutical firm, develops and commercializes CNS disorder treatments.

Public · $72.5M290
Denali TherapeuticsDenali TherapeuticsSan Francisco, CA, USBiotechest. 2015Denali TherapeuticsSan Francisco, CA, US · est. 2015

Denali Therapeutics, a US-based biotech firm, develops medicines for neurodegenerative diseases.

Public · $622M427
CuraSen TherapeuticsCuraSen TherapeuticsSan Carlos, CA, USDrugsest. 2016CuraSen TherapeuticsSan Carlos, CA, US · est. 2016

CuraSen: A biotech firm innovating drugs for CNS and neurodegenerative diseases enhancement.

Series A · $95.9M38
Kyto Technology & Life Science
Kyto Technology & Life Science

Los Altos Hills, CA, US

Board Member· Board
Epalex
Epalex
Seed$26.1M52009Palo Alto, CA, US
Board Member· Board

Recent news

With its latest acqui-hire, OpenAI is doubling down on personalized consumer AITechCrunch · 2025
AI recruiter Alex raises $17M to automate initial job interviewsTechCrunch · 2025

Leadership at Epalex

Randall MurphyRandall MurphyBoard Member
Michael RogawskiMichael RogawskiCo-Founder
Brendan MagrabBrendan MagrabBoard Member

Similar to Epalex

NeuroPaceNeuroPaceMountain View, CA, USMedical Devicesest. 1997NeuroPaceMountain View, CA, US · est. 1997

NeuroPace, a California-based manufacturer, designs and markets implantable devices for treating neurological disorders.

Public · $307.3M167
Armetheon
Armetheon
Series B$31.3M302011Menlo Park, CA, US
Board Member· Board

Leadership at Armetheon

Steven JamesSteven JamesBoard Member
Dr Larry HsuDr Larry HsuBoard Member

Similar to Armetheon

Applied TherapeuticsApplied TherapeuticsNew York City, NY, USDrug Developmentest. 2016Applied TherapeuticsNew York City, NY, US · est. 2016

Applied Therapeutics, a clinical-stage biotech firm, develops transformative drugs for critical medical needs in the US.

Public · $259.1M22
Aristea TherapeuticsAristea TherapeuticsSan Diego, CA, USDrugsest. 2018Aristea TherapeuticsSan Diego, CA, US · est. 2018

Aristea Therapeutics: Developing novel drugs for autoimmune and inflammatory diseases.

Series B · $117.6M75
Athenen TherapeuticsAthenen TherapeuticsBoston, MA, USPharmaceuticalsest. 2019Athenen TherapeuticsBoston, MA, US · est. 2019

Boston-based medical organization specializing in pharmaceuticals.

Series A · $17M5
Arete TherapeuticsArete TherapeuticsHayward, CA, USDrug Developmentest. 2003Arete TherapeuticsHayward, CA, US · est. 2003

Arete Therapeutics Inc., a US biotech firm, innovates novel drugs for diabetes, hypertension, and inflammation.

Public · $51.7M30

People Similar to Jon Saxe

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · KakaoBrian KimBrian KimBoard Member · KakaoEric ReiterEric ReiterBoard Member · KeyMeJohn NicolsJohn NicolsBoard Member · CodexisMichael GarnreiterMichael GarnreiterBoard Member · Banner HealthRebekah DoppRebekah DoppBoard Member · Tilray